10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Application of Noninvasive Vagal Nerve Stimulation to Stress-Related Psychiatric Disorders

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Vagal Nerve Stimulation (VNS) has been shown to be efficacious for the treatment of depression, but to date, VNS devices have required surgical implantation, which has limited widespread implementation. Methods: New noninvasive VNS (nVNS) devices have been developed which allow external stimulation of the vagus nerve, and their effects on physiology in patients with stress-related psychiatric disorders can be measured with brain imaging, blood biomarkers, and wearable sensing devices. Advantages in terms of cost and convenience may lead to more widespread implementation in psychiatry, as well as facilitate research of the physiology of the vagus nerve in humans. nVNS has effects on autonomic tone, cardiovascular function, inflammatory responses, and central brain areas involved in modulation of emotion, all of which make it particularly applicable to patients with stress-related psychiatric disorders, including posttraumatic stress disorder (PTSD) and depression, since dysregulation of these circuits and systems underlies the symptomatology of these disorders. Results: This paper reviewed the physiology of the vagus nerve and its relevance to modulating the stress response in the context of application of nVNS to stress-related psychiatric disorders. Conclusions: nVNS has a favorable effect on stress physiology that is measurable using brain imaging, blood biomarkers of inflammation, and wearable sensing devices, and shows promise in the prevention and treatment of stress-related psychiatric disorders.

          Related collections

          Most cited references295

          • Record: found
          • Abstract: found
          • Article: not found

          Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

          Little is known about lifetime prevalence or age of onset of DSM-IV disorders. To estimate lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the recently completed National Comorbidity Survey Replication. Nationally representative face-to-face household survey conducted between February 2001 and April 2003 using the fully structured World Health Organization World Mental Health Survey version of the Composite International Diagnostic Interview. Nine thousand two hundred eighty-two English-speaking respondents aged 18 years and older. Lifetime DSM-IV anxiety, mood, impulse-control, and substance use disorders. Lifetime prevalence estimates are as follows: anxiety disorders, 28.8%; mood disorders, 20.8%; impulse-control disorders, 24.8%; substance use disorders, 14.6%; any disorder, 46.4%. Median age of onset is much earlier for anxiety (11 years) and impulse-control (11 years) disorders than for substance use (20 years) and mood (30 years) disorders. Half of all lifetime cases start by age 14 years and three fourths by age 24 years. Later onsets are mostly of comorbid conditions, with estimated lifetime risk of any disorder at age 75 years (50.8%) only slightly higher than observed lifetime prevalence (46.4%). Lifetime prevalence estimates are higher in recent cohorts than in earlier cohorts and have fairly stable intercohort differences across the life course that vary in substantively plausible ways among sociodemographic subgroups. About half of Americans will meet the criteria for a DSM-IV disorder sometime in their life, with first onset usually in childhood or adolescence. Interventions aimed at prevention or early treatment need to focus on youth.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The role of inflammation in depression: from evolutionary imperative to modern treatment target.

            Crosstalk between inflammatory pathways and neurocircuits in the brain can lead to behavioural responses, such as avoidance and alarm, that are likely to have provided early humans with an evolutionary advantage in their interactions with pathogens and predators. However, in modern times, such interactions between inflammation and the brain appear to drive the development of depression and may contribute to non-responsiveness to current antidepressant therapies. Recent data have elucidated the mechanisms by which the innate and adaptive immune systems interact with neurotransmitters and neurocircuits to influence the risk for depression. Here, we detail our current understanding of these pathways and discuss the therapeutic potential of targeting the immune system to treat depression.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report

              This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.
                Bookmark

                Author and article information

                Journal
                J Pers Med
                J Pers Med
                jpm
                Journal of Personalized Medicine
                MDPI
                2075-4426
                09 September 2020
                September 2020
                : 10
                : 3
                : 119
                Affiliations
                [1 ]Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA; mwittbr@ 123456emory.edu (M.T.W.); mark.h.rapaport@ 123456emory.edu (M.H.R.)
                [2 ]Department of Radiology, Emory University School of Medicine, Atlanta, GA 30322, USA; jnye@ 123456emory.edu
                [3 ]Atlanta VA Medical Center, Decatur, GA 30033, USA; ajshah3@ 123456emory.edu (A.J.S.); jeanie.park@ 123456va.gov (J.P.)
                [4 ]School of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA; nil@ 123456gatech.edu (N.Z.G.); mobashir.shandhi@ 123456gatech.edu (M.H.S.); omer.inan@ 123456ece.gatech.edu (O.T.I.)
                [5 ]Department of Epidemiology, Rollins School of Public Health, Atlanta, GA 30322, USA; bpearce@ 123456emory.edu (B.D.P.); lvaccar@ 123456emory.edu (V.V.)
                [6 ]Department of Medicine, Cardiology, Emory University School of Medicine, Atlanta, GA 30322, USA
                [7 ]Department of Medicine, Renal Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
                [8 ]Department of Biomedical Engineering, City University of New York, New York, NY 10010, USA; bikson@ 123456ccny.cuny.edu
                [9 ]Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA
                Author notes
                [* ]Correspondence: jdbremn@ 123456emory.edu
                Author information
                https://orcid.org/0000-0003-1633-6433
                https://orcid.org/0000-0002-3702-0449
                https://orcid.org/0000-0001-9541-529X
                https://orcid.org/0000-0001-9099-9687
                Article
                jpm-10-00119
                10.3390/jpm10030119
                7563188
                32916852
                2008bd92-d1ea-486e-9a89-bff0f6e5e1b6
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 18 June 2020
                : 03 September 2020
                Categories
                Review

                ptsd,stress disorders,posttraumatic,depressive disorders,vagus nerve,vns,sympathetic,inflammation,interleukin-6,vagal nerve stimulation,interferon,stress

                Comments

                Comment on this article